Roche
NEWS
Veru’s enobosarm shows good proof of concept data even when 90% of patients have failed first-line therapies.
The FDA will evaluate AMX0035, an investigational oral fixed-dose drug intended for people diagnosed with ALS.
CMS says it would only cover the cost of Biogen’s Aduhelm and any required scans “if they are enrolled in qualifying clinical trials.”
The FDA’s Oncologic Drugs Advisory Committee (ODAC) has recommended 14-1 that the two companies conduct a trial applicable to the U.S. population.
To address that lack of diversity, Medable and CVS have forged a collaboration to improve patient access to clinical trial research.
Novartis CEO Vas Narasimhan and Roche CEO Severin Schwan saw revenue growth for the past year, and each took home more than $12 million in total compensation for 2021.
In Roche’s 2021 annual report, the company detailed that group sales rose 9%, pharmaceutical sales up 3%, and diagnostics up a whopping 29%.
The decision came after the Phase IIb study results demonstrating a statistically significant decrease in non-HDL-C and statistically significant reductions in triglycerides and ANGPTL3.
JOBS
IN THE PRESS